Depending on how you look at the glass half full or half empty BMSN has made great stride in the field of developing a cure for cancer. How much has it cost BMSN... compare that... to what has been spent to get where BMSN is ....by the other research labs and NO ONE HAS THE SUCCESSFULLY ACHIEVED THIS STAGE ... SAN DIEGO, CA--(Marketwired - Aug 1, 2014) - Regen BioPharma Inc. (a company majority owned by Bio-Matrix Scientific Group Inc.) (PINKSHEETS: BMSN) reported today on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors.
Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma, stated, "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA." He further noted that "Not only is this a significant milestone, but this provides additional trade secrets in our production methodology with the possibility of filing new patents on the optimized methodology and reagents we have developed."
News 
Market Data 
Discover 
